glutathione and triple negative breast cancer Ratiometrically designed nanoprodrug for triple-negative treatment Epithelial, Mesenchymal, and Hybrid triple-negative
Epithelial, Mesenchymal, and Hybrid triple negative breast cancer Download Scientific Diagram GSTP1 Is a Driver of Triple Negative Breast Cancer Cell Metabolism and Pathogenicity ScienceDirect Glutathione depletion and dihydroorotate dehydrogenase inhibition actuated ferroptosis augment to surmount triple negative breast cancer ScienceDirect NRF2 activation by cysteine as a survival mechanism for triple negative breast cancer cells Oncogene Activation of the eIF2 ATF4 axis drives triple negative breast cancer radioresistance by promoting glutathione biosynthesis ScienceDirect
Pay in 4 interest-free payments of $7.00 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9



